Predictive Technology Group (Predictive Technology Group) EBIT per Share : $-0.22 (TTM As of Mar. 2021)

View and export this data going back to 2007. Start your Free Trial

What is Predictive Technology Group EBIT per Share?

Predictive Technology Group's EBIT per Share for the three months ended in Mar. 2021 was $-0.02. Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2021 was $-0.22.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Predictive Technology Group's EBIT per Share or its related term are showing as below:

PRED's 3-Year EBIT Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 3.7
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

Predictive Technology Group's EBIT for the three months ended in Mar. 2021 was $-6.93 Mil.

Predictive Technology Group EBIT per Share Historical Data

The historical data trend for Predictive Technology Group's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Predictive Technology Group EBIT per Share Chart

Predictive Technology Group Annual Data

Trend

Aug06

Aug07

Jun16

Jun17

Jun18

Jun19

Jun20

EBIT per Share

Get a 7-Day Free Trial

-0.02

-0.05

-0.08

-0.33

Predictive Technology Group Quarterly Data
	Nov07	Feb08	May08	Jun16	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21
EBIT per Share	Get a 7-Day Free Trial															-0.04	-0.15	-0.03	-0.02	-0.02

Predictive Technology Group EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Predictive Technology Group's EBIT per Share for the fiscal year that ended in Jun. 2020 is calculated as

	EBIT per Share		(A: Jun. 2020 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-95.962	/	290.251
=	-0.33

Predictive Technology Group's EBIT per Share for the quarter that ended in Mar. 2021 is calculated as

	EBIT per Share		(Q: Mar. 2021 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-6.93	/	299.597
=	-0.02

EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.22

Predictive Technology Group (OTCPK:PRED) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Predictive Technology Group EBIT per Share Related Terms

Thank you for viewing the detailed overview of Predictive Technology Group's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Predictive Technology Group (Predictive Technology Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Predictive Technology Group Inc (OTCPK:PRED) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

2735 Parleys Way, Suite 205, Salt Lake City, UT, USA, 84109

Website

https://www.predtechgroup.com

Predictive Technology Group Inc (PRx) is a biotechnology company. It develops, commercializes, acquires and invests in technologies engaged in novel molecular diagnostic and therapeutic products in healthcare. The HCT/P segment offers minimally manipulated tissue products intended for homologous use, prepared utilizing proprietary extraction methods that reduce the loss of important scaffolding, growth factors and cytokines. The company's Diagnostics and Therapeutics segment uses data analytics for disease identification and subsequent therapeutic intervention through novel gene-based diagnostics, and companion therapeutics. It generates most of its revenues from HCT/Ps segment.